MONROVIA, CA – May 22, 2018 -- AcuraStem, Inc. has been selected as a finalist in the 2018 Start-Up Stadium event at the BIO International Convention, June 4-7 this year in Boston. As the world’s largest biotechnology event, BIO provides several specialized opportunities geared toward start-up and emerging companies. Sam Alworth, CEO and co-founder of AcuraStem, Inc. commented, “We are excited to share our innovative technology with the attendees at the upcoming BIO convention.” AcuraStem, Inc.’s President and co-founder Justin Ichida added, “This is such an opportunity for AcuraStem, and we very much look forward to utilizing this opportunity to create meaningful progress and bring hope to those affected by ALS.”
The Start-Up Stadium is designed to provide emerging companies with the opportunity to engage key members of the investment community, venture philanthropy groups, and BIO attendees. BIO is a global collective representing over 1,100 biotech companies, academic institutions, and other related organizations in more than 30 countries. Everyone at AcuraStem, Inc. is excited for this unique opportunity to bring the company’s innovative work to a much wider audience.
AcuraStem, Inc. is seeking biotech and pharma partnerships for their cutting edge iNeuroRX™ human motor neuron assessment platform as well as opportunities to partner assets in their neurodegenerative disease therapeutic pipeline. Dr. Qing Liu, co-founder of AcuraStem, Inc. will be attending the BIO International Partnering Meeting alongside Mr. Alworth. Those interested in meeting with them can reach out through the Bio Partnering portal or via email at: email@example.com.
AcuraStem, Inc. is a rapid-growing biotech company that was formed in 2016 to create an innovative precision medicine platform, iNeuroRX™, which leverages patient stem cells and advanced machine learning technology to discover drugs for neurodegenerative diseases. The platform has revealed a novel ALS target from Dr. Justin Ichida’s lab at USC. AcuraStem, Inc. is led by an exceptional team of PhDs, professors, tech entrepreneurs, and successful drug company veterans employing the latest scientific breakthroughs to first address one of the most challenging, but tractable diseases, Amyotrophic Lateral Sclerosis (ALS).
For further information, contact:
Erin Morris Huttlinger
Public Information Officer